Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 09/6/17 → 02/22/22 |
Funding
- Amgen Incorporated: $34,289.50
A Phase 1b open label study to evaluate the safety and efficacy of MPDL3280A in combination with talimogene laherparepvec in patients with triple negative breast cancer and in patients with colorectal cancer with liver metastases...
- Cohen, Jules (PI)
- Baer, Lea (CoPI)
- Stopeck, Alison (CoPI)
- Zhang, Yue (PI)
- Choi, Minsig (CoPI)
Project: Research